Clinical Trials
9 trialsNCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00059631 2018-11-15
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00103376 2018-11-05
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT00620295 2017-11-29
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00425503 2014-04-21
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Baylor College of Medicine
Phase 2 Completed
NCT00667641 2011-05-10
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT00193232 2010-07-28
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00064610 2008-02-11
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed